Company profile
PMV PHARMACEUTICALS, INC.
NASDAQ:PMVPBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| REZATAPOPT | phase1_2 | — | 5 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06054464 | phase1 | completed | 2023-09-19 | 2023-11-03 | PMV Pharmaceuticals, Inc | A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants |
| NCT06362642 | phase1 | completed | 2024-03-28 | 2024-10-22 | PMV Pharmaceuticals, Inc | A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants |
| NCT07372625 | phase1 | recruiting | 2026-02-04 | 2027-03-01 | PMV Pharmaceuticals, Inc | A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. |
| NCT05523687 | phase1 | completed | 2022-09-06 | 2022-11-30 | PMV Pharmaceuticals, Inc | AME Study of [14C]-PC14586 in Healthy Male Participants |
| NCT05249348 | phase1 | completed | 2021-12-20 | 2022-06-09 | PMV Pharmaceuticals, Inc | Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers |
FDA applications (0)
No records yet.